TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by XTX Topco Ltd

Key Points

• XTX Topco Ltd has significantly boosted its stake in TG Therapeutics by 197.8% during the first quarter, owning a total of 39,618 shares valued at approximately $1.56 million.
• Analysts have raised TG Therapeutics to a "hold" rating with a target price of $37.00, while the company has a consensus rating of "Moderate Buy" and a price target of $43.80.
• Despite a strong quarterly revenue of $120.86 million, TG Therapeutics reported an EPS of $0.03, missing analysts' expectations by $0.16.

XTX Topco Ltd raised its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 197.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,618 shares of the biopharmaceutical company's stock after buying an additional 26,314 shares during the period. XTX Topco Ltd's holdings in TG Therapeutics were worth $1,562,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of TGTX. CWM LLC increased its position in TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock worth $82,000 after purchasing an additional 290 shares during the period. Golden State Wealth Management LLC lifted its position in shares of TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 433 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of TG Therapeutics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after acquiring an additional 463 shares during the last quarter. Xponance Inc. raised its stake in TG Therapeutics by 5.3% in the 1st quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company's stock valued at $428,000 after purchasing an additional 543 shares during the last quarter. Finally, Choreo LLC boosted its stake in shares of TG Therapeutics by 7.6% during the 1st quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company's stock worth $337,000 after purchasing an additional 602 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 2.7%

Shares of TGTX traded down $0.78 during midday trading on Tuesday, hitting $27.94. The company had a trading volume of 3,381,696 shares, compared to its average volume of 2,479,043. The stock has a market cap of $4.44 billion, a price-to-earnings ratio of 116.53 and a beta of 1.95. The company's 50 day moving average price is $36.71 and its 200 day moving average price is $36.10. The company has a quick ratio of 3.04, a current ratio of 4.02 and a debt-to-equity ratio of 1.03. TG Therapeutics, Inc. has a 52 week low of $18.65 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million for the quarter, compared to the consensus estimate of $147.76 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. TG Therapeutics's quarterly revenue was up 92.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.04 EPS. On average, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 price objective on the stock in a research note on Thursday, July 10th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.80.

Insiders Place Their Bets

In other news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 10.64% of the stock is owned by insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.